Coya 302 gets fast-track designation for ALS treatment

The FDA has granted Coya 302 a fast-track designation for ALS, according to a press release from Coya Therapeutics. “ALS is a pretty devastating disease,” Fred Grossman, DO, FAPA, president and chief medical officer of Coya Therapeutics, told Healio. “People who have ALS will die essentially between 2 and 5 years after being diagnosed.”